Literature DB >> 15178578

FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways.

Daniela F Angelini1, Giovanna Borsellino, Mary Poupot, Adamo Diamantini, Rémy Poupot, Giorgio Bernardi, Fabrizio Poccia, Jean-Jacques Fournié, Luca Battistini.   

Abstract

Upon recognition of nonpeptidic phosphoantigens, human Vdelta2 T lymphocytes enter a lineage differentiation pattern that determines the generation of memory cells with a range of effector functions. Here, we show that within the effector memory Vdelta2 population, 2 distinct and complementary subsets with regard to phenotype, mode of activation, and type of responses can be identified: Vdelta2 T(EMh) cells, which express high levels of chemokine receptors, but low levels of perforin and of natural killer receptors (NKRs) and which produce large amounts of interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) in response to T-cell receptor (TCR)-specific stimulation by phosphoantigens; and Vdelta2T(EMRA) cells, which constitutively express several NKRs, high amounts of perforin, but low levels of chemokine receptors and of IFN-gamma. These NK-like cells are refractory to phosphoantigen but respond to activation via FcgammaRIII (CD16) and are highly active against tumoral target cells. Thus, circulating Vdelta2T lymphocytes comprise 2 functionally diverse subsets of effector memory cells that may be discriminated on the basis of CD16 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178578     DOI: 10.1182/blood-2004-01-0331

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  Immune regulation of gammadelta T cell responses in mycobacterial infections.

Authors:  Zheng W Chen
Journal:  Clin Immunol       Date:  2005-09       Impact factor: 3.969

4.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 5.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

6.  Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Authors:  Gabriele Pizzolato; Hannah Kaminski; Marie Tosolini; Don-Marc Franchini; Fréderic Pont; Fréderic Martins; Carine Valle; Delphine Labourdette; Sarah Cadot; Anne Quillet-Mary; Mary Poupot; Camille Laurent; Loic Ysebaert; Serena Meraviglia; Francesco Dieli; Pierre Merville; Pierre Milpied; Julie Déchanet-Merville; Jean-Jacques Fournié
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

7.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

8.  Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Authors:  A Bertaina; A Zorzoli; A Petretto; G Barbarito; E Inglese; P Merli; C Lavarello; L P Brescia; B De Angelis; G Tripodi; L Moretta; F Locatelli; I Airoldi
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

9.  Interleukin-18 activates Vγ9Vδ2+ T cells from HIV-positive individuals: recovering the response to phosphoantigen.

Authors:  Alanna S Murday; Suchita Chaudhry; C David Pauza
Journal:  Immunology       Date:  2017-05-24       Impact factor: 7.397

10.  FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia.

Authors:  Daniel M Schreeder; Jicun Pan; Fu Jun Li; Eric Vivier; Randall S Davis
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.